Tag Archives: glucagon-like peptide-1 (GLP-1) receptor agonists

Introduction Obesity and cardiovascular disease In England, two thirds of adults are now living with overweight or obesity.1,2 About 40% of deaths attributable to a high body mass index (BMI) are due to cardiovascular disease.3 Coupled with being intimately linked to prevalent cardiovascular risk factors, such as hypertension, dyslipidaemia and type 2 diabetes (T2D), obesity, directly and indirectly, contributes to almost all cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure and atrial fibrillation (AF).4 All clinicians involved in the care of patients with cardiovascular disease will inevitably encounte